Junjie Xiao

Junjie Xiao

Auto-generated profile, based on publicly available information

Junjie Xiao

College of Pulmonary & Critical Care Medicine, Chinese PLA General Hospital Beijing China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 February 2023 in Immune Network
Verified
Journal Article
Open access
PDF file
FHFei Hou
Fei Hou
HWHuan Wang
Huan Wang
KZKun Zheng
Kun Zheng
WYWenting Yang
Wenting Yang
KXKun Xiao
Kun Xiao
Lixin XieLixin Xie
Lixin Xie
Hou F, et al. Immune Netw. 2023 Feb;23(3):e24. https://doi.org/10.4110/in.2023.23.e24

11 December 2024 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
JXJunjie Xiao
Junjie Xiao
FHFei Hou
Fei Hou
HWHuan Wang
Huan Wang
RWRuixuan Wang
Ruixuan Wang
YLYing Liu
Ying Liu
Lixin XieLixin Xie
Lixin Xie
Introduction: Acute lung injury (ALI) and its subsequent progression to acute respiratory distress syndrome (ARDS) are severe respiratory conditions. They are marked by rapid lung function deterioration and extensive pulmonary inflammation, often resulting in critical patient outcomes. Alveolar macrophages (AMs) and monocyte‐derived macrophages (MDMs) are two distinct subsets of lung macrophages present in the alveoli during ALI. Both are critical mediators of pulmonary inflammation. Our study examined the interplay between AMs and MDMs in the inflammatory environment of ALI/ARDS.Methods: Mice were treated with lipopolysaccharide (LPS) to establish ALI models. The lung tissues of mice were subjected to hematoxylin‐eosin staining to observe the degree of tissue damage. In vivo, CCR2‐deficient mice or depleting peripheral blood mononuclear cells by clodronate liposomes were used to reduce MDMs recruitment. The bronchoalveolar lavage fluid (BALF) supernatants were used for cytokine and total protein analyses. AMs and MDMs in the BALF were analyzed by flow cytometry. The levels of AMs death were determined through propidium iodide staining and measured by flow cytometry. In vitro, primary AMs were exposed to MDM‐conditioned medium or TNF‐α, and their death levels were assessed under a fluorescence microscope with propidium iodide staining.Results: AMs significantly decrease in number and undergo extensive cell death during ALI. The reduced MDMs recruitment can increase the number of AMs, reduce AMs death, and alleviate lung injury. In vitro, MDM‐conditioned medium can induce AMs death and TNF‐α is one of the major secretions. It indicates that TNF‐α stimulation in vitro promotes AMs death. In vivo, MDMs are identified as the primary cells secreting TNF‐α. Additionally, the treatment with TNF‐α antagonists can reduce AMs death and the severity of lung injury.Conclusion: Our study demonstrates that MDMs contribute to AMs death during ALI through TNF‐α. Targeting TNF‐α may offer a therapeutic strategy to mitigate AMs death and lung injury in ALI/ARDS.

1 May 2023 in Journal of Biomedical Nanotechnology
Verified
Journal Article
Closed access
WGWei Guan
Wei Guan
YSYinghan Shi
Yinghan Shi
JXJiaruo Xu
Jiaruo Xu
XWXiuli Wang
Xiuli Wang
JXJunjie Xiao
Junjie Xiao
Lixin XieLixin Xie
Lixin Xie
This study aimed to investigate the therapeutic potential of dasatinib, an FDA-approved drug for chronic myeloid leukemia, in sepsis-induced acute lung injury (ALI). In the in vitro part of the study, RAW 264.7 macrophages were stimulated with lipopolysaccharide (LPS), and the anti-inflammatory effects of dasatinib were assessed by measuring pro-inflammatory mediators and cytokines. In the in vivo part, ALI was induced in mice through intraperitoneal LPS injection. The researchers investigated alveolar-capillary permeability, the inflammatory response, and the therapeutic efficacy of dasatinib in ALI. Dasatinib administration was found to attenuate inflammation by inhibiting the mTOR pathway. In the in vivo experiments, dasatinib reduced the levels of pro-inflammatory cytokines and chemokines in bronchoalveolar lavage fluid (BALF). It also decreased lung tissue permeability, as evidenced by a lower amount of Evans blue dye detected after ALI. Furthermore, dasatinib alleviated lung histological damage and reduced the lung injury grade, demonstrating its protective role in ALI. By inhibiting the mTOR pathway in macrophages, dasatinib exhibited a protective and anti-inflammatory effect on ALI. It reduced the intrapulmonary inflammatory response, prevented capillary disruption, and inhibited the accumulation of inflammatory cells. These findings suggest that dasatinib holds promise as a potential treatment option for protecting lung tissue in ALI.